▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1421 by analyst upside · 2026-11-12
MIRM
Mirum Pharmaceuticals, Inc.
Healthcare · Market Cap $6B · P/E 0x
ANALYST PRICE TARGET
+62.8%
implied upside to consensus target
Current Price $94.61
Consensus Target $154.0
Bull Target $194.0
Bear Target $118.0
Analysts Covering 12
ANALYST CONSENSUS - BUY
Strong Buy
4
Buy
8
Hold
0
Sell
0
52-Week Low $63.23
52-Week High $130.0
YTD Return +21.2%
FUNDAMENTALS
Market Cap $6B
P/E Ratio (TTM) N/A
Forward P/E 295.7x
EPS (TTM) $-14.48
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $671M
Profit Margin -134.8%
52-WEEK RANGE
52-Week Low $63.23
52-Week High $130.0
Current Price $94.61
Bear Target $118.0
Bull Target $194.0
● Now $94.61 ● Target $154.0
TRADING DATA
Avg Volume 692K
YTD Return +21.2%
Analyst Count 12
Consensus Buy
Upside to Target +62.8%
Last Updated 2026-11-12

ANALYST SUMMARY

Mirum Pharmaceuticals, Inc. (MIRM) is currently trading at $94.61 with a Wall Street consensus price target of $154.0, implying potential upside of 62.8% over the next 12 months. 12 analysts currently cover MIRM, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $194.0, while the most cautious has a target of $118.0.

MIRM operates in the Healthcare sector with a market capitalisation of $6B. The stock is up 21.2% year-to-date and is currently trading near the lower end of its 52-week range of $63.23 – $130.0.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

GRFS +17.3%
Grifols, S.A.
$6B · P/E 10.7x · Buy
CAI +39.8%
Caris Life Sciences, Inc.
$7B · P/E 14.8x · Buy
EWTX +16.5%
Edgewise Therapeutics, Inc.
$5B · P/E 5.6x · Buy
INDV +36.4%
Indivior Pharmaceuticals Inc
$4B · P/E 10.2x · Buy
LNTH +4.3%
Lantheus Holdings, Inc.
$7B · P/E 25.3x · Hold

RECENT ANALYST CALLS

Upgrade/downgrade history for MIRM, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Leerink Partners - Reiterated
Outperform → Outperform 2026-11-05 29% win rate (7 calls)
RBC Capital reit
Outperform → Outperform 2026-11-04 Building track record
Citizens - Reiterated
Market Outperform → Market Outperform 2026-11-04 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-11-04 31% win rate (48 calls)
Cantor Fitzgerald - Reiterated
Overweight → Overweight 2026-11-04 40% win rate (10 calls)
TD Cowen - Reiterated
Buy → Buy 2026-10-21 Building track record
Stifel - Reiterated
Buy → Buy 2026-10-15 Building track record
Evercore ISI Group - Reiterated
Outperform → Outperform 2026-10-13 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
61
out of 100
Coverage depth
20/30
Consensus clarity
14/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →